Q-omics provides the consensus-scored TRIM58 profile across patient tissues and cancer cell-line models. TRIM58 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, TRIM58 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, TRIM58 RNA expression shows 17,479 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUSC, THCA, and THYM as cancer lineages where TRIM58 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM58 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM58 survival associations across molecular data types. TRIM58 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM58 RNA expression–survival associations across cancer types. High TRIM58 expression shows unfavorable associations in LUSC, COAD, UCEC and KIRP, but favorable associations in KIRC and BRCA. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for TRIM58 RNA expression.
This table summarizes TRIM58 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TRIM58. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM58 shows lower tumor expression in THCA, COAD, LUAD, LUSC and STAD and higher tumor expression in BRCA. The THCA box plot shows higher TRIM58 RNA expression in normal versus tumor tissue (log2 FC = −2.989, t-test p < 0.001).
This table shows molecular features associated with TRIM58 in patient tissues and cancer cell lines. In patient samples, TRIM58 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM58 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
